Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
New follow-up data for the Oncotype DX GPS assay
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Have questions? We're here to help.